Treatment advances in small cell lung cancer (SCLC)
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference83 articles.
1. Southwest Oncology Group S0802: A randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer;Allen;Journal of Clinical Oncology,2014
2. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial;Antonia;The Lancet Oncology,2016
3. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
4. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20;Arnold;Journal of Clinical Oncology,2007
5. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group;Auperin;The New England Journal of Medicine,1999
Cited by 135 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Synergistic effect of a nonsteroidal anti-inflammatory drug in combination with topotecan on small cell lung cancer cells;Molecular Biology Reports;2024-01-18
2. A Stacking Approach Based on Machine Learning Techniques for Lungs Cancer Prediction in Healthcare Systems;2023 20th International Computer Conference on Wavelet Active Media Technology and Information Processing (ICCWAMTIP);2023-12-15
3. The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases;Frontiers in Pharmacology;2023-12-06
4. Extracellular vesicles from non‐neuroendocrine SCLC cells promote adhesion and survival of neuroendocrine SCLC cells;PROTEOMICS;2023-11-05
5. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings;Immunotherapy;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3